Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019 Aug;44(4):495-507. doi: 10.1111/jcpt.12830
Blonde L, Brunton SA, Chava P, Zhou R, Meyers J, Davis KL, Dalal MR, Digenio A. Achievement of target A1C <7.0% (<53 mmol/mol) by U.S. type 2 diabetes patients treated with basal insulin in both randomized controlled trials and clinical practice. Diabetes Spectr. 2018 Nov;31(4). doi: 10.2337/ds17-0082
Setji T, Hopkins TJ, Jimenez M, Manning E, Shaughnessy M, Schroeder R, Mendoza-Lattes S, Spratt S, Westover J, Aronson S. Rationalization, development, and implementation of a preoperative diabetes optimization program designed to improve perioperative outcomes and reduce cost. Diabetes Spectr. 2017 Aug;30(3):217-23.
Goyal RK, Rajan SS, Essien EJ, Sansgiry SS. Effectiveness of FDA's new over-the-counter acetaminophen label warning requirements in improving consumer risk perception of liver damage. J Clin Pharm Ther. 2012 Dec;37(6):681-5. doi: 10.1111/j.1365-2710.2012.01371.x.